+ T lymphocytes (CTLs) specific for antigenic peptides derived from internal viral proteins confer broad protection against distinct strains of influenza A virus (IAV). However, immune efficacy can be undermined by the emergence of escape mutants. To determine how T-cell receptor (TCR) composition relates to IAV epitope variability, we used ex vivo peptide-HLA tetramer enrichment and single-cell multiplex analysis to compare TCRs targeted to the largely conserved HLA-A*0201-M1 58 and the hypervariable HLA-B*3501-NP 418 antigens. The TCRαβs for HLA-B*3501-NP 418 + CTLs varied among individuals and across IAV strains, indicating that a range of mutated peptides will prime different NP 418 -specific CTL sets. Conversely, a dominant public TRAV27/TRBV19
Memory CD8
+ T lymphocytes (CTLs) specific for antigenic peptides derived from internal viral proteins confer broad protection against distinct strains of influenza A virus (IAV). However, immune efficacy can be undermined by the emergence of escape mutants. To determine how T-cell receptor (TCR) composition relates to IAV epitope variability, we used ex vivo peptide-HLA tetramer enrichment and single-cell multiplex analysis to compare TCRs targeted to the largely conserved HLA-A*0201-M1 58 and the hypervariable HLA-B*3501-NP 418 antigens. The TCRαβs for HLA-B*3501-NP 418 + CTLs varied among individuals and across IAV strains, indicating that a range of mutated peptides will prime different NP 418 -specific CTL sets. Conversely, a dominant public TRAV27/TRBV19
+ TCRαβ was selected in HLA-A*0201
+ donors responding to M1 58 . This public TCR cross-recognized naturally occurring M1 58 variants complexed with HLA-A*0201. Ternary structures showed that induced-fit molecular mimicry underpins TRAV27/TRBV19
+ TCR specificity for the WT and mutant M1 58 peptides, suggesting the possibility of universal CTL immunity in HLA-A*0201 + individuals. Combined with the high population frequency of HLA-A*0201, these data potentially explain the relative conservation of M1 58 . Moreover, our results suggest that vaccination strategies aimed at generating broad protection should incorporate variant peptides to elicit cross-reactive responses against other specificities, especially those that may be relatively infrequent among IAV-primed memory CTLs.
influenza infection | human CD8 + T cells | T-cell receptor P reexisting CD8 + T-lymphocyte (CTL) immunity directed at peptides derived from internal viral proteins is known to confer protection against specific strains of influenza A virus (IAV) (1) (2) (3) (4) (5) . Recalled memory CTLs generated by seasonal variants can also expedite virus elimination and host recovery following infection with H1N1, H2N2, H3N2, H5N1, and H7N9 IAVs (2, 3, (6) (7) (8) (9) . However, it is unclear why such cross-strain responses vary among individuals. The ability of αβ T-cell receptors (TCRαβs) to recognize antigenic epitopes from distinct IAVs and circumvent immune escape relies on peptide sequence conservation and/or structural homology (10) (11) (12) . A detailed understanding of cross-strain reactivity in relation to defined TCRαβ interactions may therefore inform the rational development of a universal vaccine against IAV.
The conserved HLA-A*0201-restricted M1 58-66 (GILGFVFTL, referred to hereafter as "M1 58 ") (13) and variable HLA-B*07 superfamily-restricted NP [418] [419] [420] [421] [422] [423] [424] [425] [426] (LPFERATVM, referred to hereafter as "NP 418 ") (10) peptides are the most immunogenic IAV epitopes described in humans. The M1 58 epitope has remained unchanged in seasonal and pandemic IAVs since 1918 (1, 8, 14, 15) , although viruses with single-alanine-substitution mutants of M1 58 generated by reverse genetics are replication competent (16) . Accordingly, the M1 58 peptide is an ideal vaccine candidate for >1 billion people globally who express HLA-A*0201. In contrast, the NP 418 epitope is hypervariable, encompassing >20 different naturally occurring sequences. Analysis of HLA-B*07/B*35-restricted NP 418 -specific CTLs in the wake of the 2009 pandemic revealed at least two distinct responses to this prominent epitope (12) .
In this study, we used ex vivo tetramer enrichment combined with single-cell multiplex RT-PCR to dissect TCRαβ signatures within CTL populations specific for the HLA-A*0201-M1 58 and HLA-B*07/B*35-NP 418 epitopes. Our data indicate that public A*0201-TCRαβs use molecular mimicry to recognize distinct IAVs.
Results
Natural IAV M1 58 Variants Emerge in HLA-A2.1 Transgenic HHD Mice.
The HLA-A*0201-restricted M1 58 peptide is broadly conserved across IAVs, although the M1-I2M and M1-L3W variants have been found in 21% of H5N1 sequences (7) . Using the influenza resource database at the National Center for Biotechnology Information, we aligned 1,000 full-length sequences representing IAV subtypes infecting different species between 1918 and 2010 to conduct an in-depth validation of M1 58 conservation.
Significance
Influenza is a rapidly spreading acute respiratory infection that causes profound morbidity and mortality. Established CD8 + T-lymphocyte (CTL) immunity directed at conserved viral regions provides protection against distinct influenza A viruses (IAVs). In this study, we show that public T-cell receptors (TCRs) specific for the most prominent human CTL epitope (M1 58-66 restricted by HLA-A*0201) are capable of recognizing sporadically emerging variant IAVs. We also identify the structural mechanisms that enable promiscuous TCR recognition in this context. Our analysis suggests that preexisting cross-reactive TCRs may limit the spread of newly emerging pandemic IAVs.
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The authors declare no conflict of interest. (17) . Engineered PR8 viruses carrying the M1-I2M, M1-F5L, M1-V6I, and M1-F7Y mutations grew to similar titers in embryonated eggs and MDCK cell cultures (Fig. S1 F and G) . However, it remains possible that subtle differences in viral fitness may counterselect against M1 58 mutants in the natural setting. The absence of epitopespecific immune pressure also may lead to the occurrence of viral refugia in individual cases, a phenomenon widely recognized in the ecology field.
Sequence variation within M1 58 therefore occurs in IAVs recovered from humans (8.2%) and from experimentally infected HLA-A2.1 HHD mice (7.3%). However, unlike the frequent and persistent mutations in NP 418 (10) Table S1 ). A2-M1 58 + CTLs were identified with a single conserved tetramer, and B35-NP 418 + CTLs were identified with a tetramer pool corresponding to the main variants from 1918, 1934, 1947, 1980, and 2002 (12) . The A2-M1 58 + CTL population was consistently larger (17 ± 9.2-fold) than the B35-NP 418 + CTL population (Fig. 1A) , which frequently predominates in HLA-A*0201
− donors (Fig. S2) . Furthermore, the polyclonal A2-M1 58 + CTLs recognized all detected mutants, although response frequencies varied and the M1-G4E mutant was weakly immunogenic in five donors (Fig. 1B) . Conversely, the polyclonal B35-NP 418 + CTLs recognized a limited number of variants ( Fig. 1C ), in line with previous reports of immune escape (10, 12) . Thus, M1 58 -specific TCRs cross-react with a broader spectrum of naturally occurring epitope variants compared with NP 418 -specific TCRs. It is notable in this regard that NP 418 variants are often composite, incorporating up to three amino acid substitutions, whereas single mutations are more common in M1 58 .
Dissection of A2-M1 58 and B35-NP 418 TCRαβ Repertoires. Consistent with previous reports (19) (20) (21) , direct ex vivo single-cell sequencing of the A2-M1 58 + TCRαβ repertoire showed a heavy bias toward T-cell receptor β variable 19 (TRBV19) use across all eight donors, coupled with a dominant T-cell receptor α variable 27 (TRAV27) segment in seven of eight donors ( Fig. 2 A and B and Fig. S3 A and B). The averaged frequency for TRBV19 was 91.6% (range 44-100%), compared with 49.2% (range 0-91%) for TRAV27. The most common TCRαβ signature was the public clonotype TRBV19/complementarity-determining region (CDR)3β-SIRSSYEQ paired with TRAV27/CDR3α-GGSQGNL (Fig. 2C and Fig. S3 C-E). In subject 23, the public TRBV19/CDR3β-SIRSSYEQ paired with a similar TRAV27/CDR3α-ASGSSNTGKL (44% of sequences), whereas subject 22 exhibited a limited TCRαβ repertoire in which an alternate TCRβ (TRBV19/CDR3β-GAGGPLNEQ) paired with a non-TRAV27 TCRα (TRAV12.3/CDR3α-SERNNARL). Public TCRαβ clonotypes can therefore be generated in the majority of HLA-A2 + individuals across different ethnicities, including Indigenous Australians.
Reflecting the prevalence of low-frequency private clonotypes, the M1 58 -specific TCRαβ repertoire was more diverse (12.4 ± 6.0 CDR3αβ pairs per donor) than previously reported. Furthermore, the AGA(G n )GG CDR3α motif (22) (in which " n " denotes any number of residues) found by others following long-term culture was not consistently present in our direct ex vivo dataset, although two glycines (GG) featured in 20 of the 45 CDR3α sequences. The CDR3β IRS motif, which forms the basis for "peg-notch" JM22 TCR recognition of the "plain vanilla" M1 58 epitope (21), was used in 11/45 CDR3β sequences across five donors.
In contrast, analysis of the B35-NP 418 + TCR repertoire using pooled B35-NP 418 tetramers (Fig. S4 ) revealed distinct CDR3α/ CDR3β sequences incorporating diverse TRAV and TRBV segments. A preference for TRBV20-1/TRBJ5-1 rearrangements with a CDR3β length of 7 or 10 amino acids was observed in the TCRβ repertoire, whereas the predominant TCRα chains favored TRAV8-1 and TRAJ18 with a CDR3α length of 8-10 amino acids (Table S2) . However, only one common sequence (TRAV8-1/CDR3α-NEGGSTLGRL) was found among individuals (Fig. S4) .
There was no overlap between the B35-NP 418 + TCR datasets, generating a Morisita-Horn statistic of 1 (zero interindividual similarity). However, the A2-M1 58 + TCR datasets overlapped considerably, driven by the public TRBV19/CDR3β-SIRSSYEQ sequence (averaged Morisita-Horn statistic of 0.6). These differences were statistically significant (P = 0.0056, Wilcoxon signed tank test). In addition, the Simpson diversity index was higher for B35-NP 418 + TCRαβs (0.97 ± 0.03) than for A2-M1 58 + TCRαβs (0.75 ± 0.27) (Table S2) . Thus, dominant public TCRαβ clonotypes (TRBV19/TRAV27) are selected in HLA-A*0201
+ donors responding to the relatively invariant A2-M1 58 epitope, whereas TCRαβ clonotypes directed at the hypervariable B35-NP 418 epitope are more diverse across individuals.
Public M1 58 -Specific TCRαβ Clonotypes Cross-Recognize Newly Identified Variants. How do A2-M1 58 + CTLs recognize naturally occurring M1 58 variants? To investigate this question, peripheral blood mononuclear cells (PBMCs) were stimulated with the mutant peptide (M1-L3W, -G4E, or -F5L) for 10 d and then stained with the M1 58 WT tetramer. In this way, variant-specific CTLs were amplified by the mutant peptide, and cross-reactive clonotypes identified by reactivity with the M1 58 WT tetramer were characterized using single-cell CDR3αβ TCR repertoire diversity analysis ( Fig. 3 and Table S3 ). The variant M1-L3W, M1-G4E, and M1-F5L peptides represent naturally occurring M1 58 mutants, with a CTL response magnitude hierarchy of M1-L3W > M1-F5L > M1-G4E in subject 9 and subject 16 (Fig. 3) .
The public HLA-A*0201-M1 58 + TCR (CDR3α-GGSQGNL; CDR3β-SIRSSYEQ) recognized all three peptide variants (Table  S3) , although the frequency was slightly lower for the M1-G4E mutant (47% of the WT). Higher-frequency public TCRαβ use correlated with larger mutant-specific CTL responses (Fig. 1B) , indicating that public HLA-A*0201-M1 58 + TCRs play an important role in variant cross-recognition. Overall, the mutant M1 58 peptides selected a TCRαβ repertoire comparable to that of WT M1 58 with similar TRAV27, TRAJ42, TRBV19, and TRBJ2-7 use (except for M1-G4E in subject 16, which used TRAV23DV/6 instead of the typically dominant TRAV27), suggesting that WT HLA-A*0201-M1 58 + TCRs are largely cross-reactive with M1 58 variants.
HLA Presentation and TCR Recognition of M1 58 Variants. To determine the impact of peptide mutation on HLA binding and T-cell recognition, we assessed the extent to which the naturally occurring M1 58 mutant peptides M1-F5L, M1-G4E, and M1-L3W stabilize HLA-A*0201. We refolded the HLA-A*0201 molecule with the M1 58 peptide and each of the three variants to determine the thermal stability of the corresponding peptide-HLA (pHLA) complexes. In complex with the M1 58 peptide, HLA-A*0201 exhibited a thermal melt point (Tm, the temperature required to unfold 50% of the protein) of ∼66°C; the Tm was similar for the three M1 58 variants (Table S4 ), indicating that the mutations directly affect TCR binding rather than pHLA complex stability.
To understand the mode of recognition of M1 58 mutants by public HLA-A*0201-M1 58 + TCRs, we conducted surface plasmon resonance studies with the previously characterized M1 58 -specific JM22 TCR (TRAV27/CDR3α-AGSQGNL; TRBV19/ CDR3β-SSRSSYEQ) (21) . We confirmed that the JM22 TCR binds with high affinity (1.79 μM) to the HLA-A*0201-M1 58 complex (21, 23), but measured substantially lower affinities for the three M1 58 variants (Table S5) . Namely, weak binding (K d >200 μM) characterized the JM22 TCR interaction with M1-G4E and M1-F5L, and this was further diminished (K d >600 μM) for M1-L3W, presented by HLA-A*0201 (Table S5) . Thus, although the JM22 TCR can recognize all M1 58 variants, the binding affinity is lower for the mutant epitopes (24) . M1-L3W) (Fig. 4 and Table S6 ) and compared these structures with the previously solved structure of HLA-A*0201-M1 58 (23) . The M1 58 epitope is considered plain vanilla because the M1 58 epitope adopts a flat surface in the cleft of HLA-A*0201 (25) (Fig. 4A) . Indeed, despite containing two aromatic residues (P5-Phe and P7-Phe), these side chains are buried inside the antigenbinding cleft, leaving the P6-Val solvent exposed. The overall structure of the M1-G4E mutant complex is similar to that of the M1 58 complex, with rmsds of 0.25 Å for the antigen-binding cleft and 0.27 Å for the peptide (Fig. 4A) . Although the replacement of the glycine residue by glutamic acid does not disturb the backbone conformation for M1-G4E, it allows P6-Val to move deeper into the HLA-A*0201 antigen-binding cleft (Fig. 4A) . As a result, P5-Phe and P7-Phe are mobile and adopt several conformations, most of which are solvent exposed (Fig. 4A) . More dramatic rearrangements were observed for the M1-L3W (Fig. 4B) and M1-F5L (Fig. 4C) variants. The P3-Leu of the WT M1 58 peptide is buried in the cleft and interacts with the B pocket of HLA-A*0201, whereas the larger P3-Trp of M1-L3W is accommodated in the B pocket without modification of the overall antigen-binding cleft structure (rmsd of 0.33 Å). However, the M1-L3W peptide must rearrange dramatically due to the presence of the large tryptophan residue at P3 (rmsd of 0.61 Å) (Fig. 4B) . The P5-Phe side chain swings out of the antigen-binding cleft to avoid steric clashes with P3-Trp and hence becomes solvent exposed. As a consequence, P6-Val is buried in the antigen-binding cleft, and P7-Phe is again mobile and solvent exposed (Fig. 4B) . Thus, in the HLA-A*0201-M1-L3W structure, the two large aromatic side chains at P5 and P7 are directly available for TCR interaction.
Similarly, the M1-F5L variant adopts a different peptide conformation (rmsd of 0.44 Å) without distorting the antigen-binding cleft (rmsd of 0.29 Å) (Fig. 4C) . Even though P5-Leu is smaller than P5-Phe, the rotamer of the leucine side chain (like P5-Phe) does not allow docking inside the antigen-binding cleft without changing the overall backbone of the peptide. The P3-Leu therefore no longer interacts with the B pocket of HLA-A*0201 and instead becomes mobile and solvent exposed. The new conformation of the P5-Leu residue also impacts the P6-Val conformation, which becomes buried in the antigen-binding cleft, whereas P7-Phe is now solvent exposed and mobile (Fig. 4C) .
Overall, these surprising structures of the M1 58 variants demonstrate that interplay between peptide residues constrains the conformation of the M1 58 epitope, with any alterations reflecting either the inherent flexibility of particular residues (in M1-G4E and M1-F5L) or steric hindrance (in M1-L3W). As a consequence, single substitutions at different positions in the peptide can transform the plain vanilla M1 58 epitope into a more featured antigen.
The Public JM22 TCR Recognizes M1 58 Variants via Induced-Fit Molecular Mimicry. To understand how HLA-A*0201-M1 58 + CTLs recognize the naturally occurring epitope variants (Fig. 1B) , we determined the structures of the JM22 TCR (21) in complex with HLA-A*0201-M1-G4E and HLA-A*0201-M1-F5L (Table S7) . As in the WT M1 58 complex (Fig. 4 D-F) , the JM22 TCR docks orthogonally on the two M1 58 variant peptides presented by HLA-A*0201 (rmsd of 1.1 Å and 0.7 Å with the M1-G4E and M1-F5L complexes, respectively). The M1-G4E and M1-F5L peptides change conformation upon JM22 TCR binding (Fig. 4 G and  H) to mimic that of the WT M1 58 peptide (Fig. 4I) . These structural rearrangements allow key residues (23) from the JM22 TCR β-chain (identified via mutagenesis), namely D32, Q52, and R98, to maintain critical interactions with both the peptide and HLA-A*0201. The requirement for conformational change also explains why the JM22 TCR binds HLA-A*0201-M1-G4E and HLA-A*0201-M1-F5L with lower affinities than HLA-A*0201-M1 58 (Fig. 4 G and H) .
The leucine substitution at p5 (M1-F5L) is accommodated without rearrangements of the JM22 TCR CDR loops (Fig. 4J) (23) , whereas the JM22 TCR docking angle is slightly different when in complex with M1 58 and M1-G4E (78°and 80°, respectively) (Fig. 4  D and F) . This difference is a direct result of the P4-Glu substitution, which causes a 1-Å shift of the CDR3α loop to avoid steric clashes with the P4-Glu (Fig. 4K) . The key JM22 TCR β-chain residues identified via mutagenesis (23), namely D32, Q52, and R98, conserve their critical interactions with both the peptide and the HLA molecule despite the P4-Glu and P5-Leu substitutions. Thus, the lower affinity of the JM22 TCR for HLA-A*0201-M1-F5L and HLA-A*0201-M1-G4E can be attributed to structural changes in the corresponding peptides, as well as to the CDR3α loop in the case of M1-G4E, following TCR binding (Fig. 4 G and H, respectively). Given the structural rearrangement of the M1-G4E and M1-F5L peptides, it is anticipated that large changes would occur in the M1-L3W peptide, resulting in an even lower affinity for the JM22 TCR (Table S5) .
These ternary structures show that a public TCRαβ can recognize naturally occurring M1 58 variants via induced-fit molecular mimicry, potentially explaining why this epitope is conserved among influenza viruses circulating in the human population.
Discussion
Diversity in the TCR repertoire has been associated with highavidity recognition of MHC-peptide antigens, effective viral clearance, and the containment of immune escape (26, 27) . In this study, we used a multiplex single-cell RT-PCR (28, 29) to determine whether TCRαβ diversity and/or composition are associated with immune escape in influenza virus infection. The broad recognition spectrum of a public TRAV27/TRBV19 + TCR within the M1 58 -specific CTL repertoire correlated with the relative scarcity of naturally occurring epitope variants. Such public A2-M1 58 + TCRs were found to be highly prevalent across donors, including HLA-A*0201 + non-Indigenous donors and Indigenous Australians (HLA-A*0201 frequency of 30-50% and 10-15%, respectively). It is notable in this regard that Indigenous Australians are at greater risk of severe influenza disease, especially when new IAVs emerge (9, 30, 31) . Nonetheless, preexisting CTL memory characterized by best-fit public TCRs may confer protection in the context of HLA-A*0201.
The ternary structure of a public TCR bound to the plain vanilla HLA-A*0201-M1 58 complex (21, 23) showed previously that the central arginine residue within the predominant CDR3β IRS motif (21) is required to allow a peg-notch interaction. We extended this analysis to naturally occurring M1 58 mutants and found that the A B same public TCR can recognize naturally occurring variants via induced-fit molecular mimicry, incurring a penalty in terms of binding affinity and T-cell activation. Moreover, the extent of variant recognition correlated with the prevalence of public TCRs, possibly explaining the hierarchical differences in TCR affinity (G4E/F5L > L3W) and T-cell activation (L3W > F5L > G4E). Donors with prominent public TCR use (e.g., subject 9, 67%) recognized the majority of M1 58 mutants, and the converse was true for donors with limited public TCR use (e.g., subject 16, 15%). These observations suggest that public TCRs may limit, at least to some extent, the establishment of mutant strains within the circulating pool of human IAVs. This idea is consistent with an earlier report in which public Mamu-A*01-CM9 181 -specific TCRs were shown to predict the outcome of simian immunodeficiency virus infection in rhesus macaques (32) . Mutant peptides incorporating substitutions at TCR contact sites within the B35-NP 418 epitope (reflecting nine decades of natural selection) can be recognized by at least two distinct sets of cross-reactive CTLs specific for either ER or DK motifs at P4-5 (11). In theory, accurate identification of the key solventexposed residues and motifs that allow variable peptides to elicit cross-reactive CTL responses could inform the development of rationally designed peptide-mosaic vaccines against unpredicted IAVs (1, 33) . Unlike the A2-M1 58 + CDR3αβ repertoire, however, the NP 418 + CDR3αβ repertoire in B7 + and B35 + donors is diverse and private, potentially facilitating the emergence of novel NP 418 variants. In turn, these mutated epitopes will likely elicit de novo TCR repertoires. Successive waves of variant exposure and diverse TCR recruitment may therefore favor the emergence and perpetuation of NP 418 mutant IAVs (34) .
Structural analyses revealed that single-amino acid substitutions within the M1 58 peptide can transform this rather flat epitope into conformations that are no longer plain vanilla (25) . Although the featureless morphology of HLA-A*0201-M1 58 determines the character of the highly biased TCR repertoire (21, 25) , our data show that structurally prominent M1 58 variants select a similar array of TCRs. This counterintuitive finding can be explained, at least in part, by the observation that public TCRs (exemplified by JM22) can reshape such variants into conformations that resemble the WT M1 58 epitope, which is optimal for immediate binding without the need for structural rearrangements. Such induced-fit molecular mimicry was reported previously for an Epstein-Barr virus-specific TCR (35) .
In summary, we show here that HLA-A*0201-restricted public TCR clonotypes elicited by the WT M1 58 epitope can crossrecognize naturally occurring peptide variants. Conversely, the HLA-B*3501-restricted NP 418 epitope selects a diverse and largely private CDR3αβ repertoire, which correlates with frequent mutational escape and the ongoing circulation of variant IAVs (12, 16) . The ability of vaccine-induced CTL responses to protect against variable pathogens should therefore be considered in the context of individual peptides and individual TCRs.
Methods
PBMC Isolation. PBMCs were processed and HLA-typed from randomly selected buffy packs (Melbourne Blood Bank) and healthy donors, with informed written consent (Table S1) sorted using a FACSAria (BD Biosciences) into 96-well plates. CDR3αβ regions were determined using a single-cell multiplex RT-PCR (28, 29) . Sequences were analyzed with FinchTV, and V/J regions were identified by IMGT.
Intracellular Cytokine Staining (ICS). PBMCs were stimulated with peptides for 10 d, and IAV-specific CTLs were quantified using IFN-γ/TNF-α ICS (12, 33 (17) . The M1 region was amplified and sequenced.
Recombinant Influenza Viruses. Influenza viruses with amino acid substitutions in the M1 58 peptide (M1-I2M, M1-F5L, M1-V6I, and M1-F7Y) were generated using reverse genetics and amplified in embryonated eggs (38) . Protein chemistry and structural biology are described in SI Methods.
